Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Neurology"
DOI: 10.1007/s00415-017-8410-6
Abstract: Intravenous tissue plasminogen activator (tPA) thrombolysis remains the only proven pharmacological treatment for acute ischemic stroke [1]. A common clinical scenario is where a patient with atrial fibrillation (AF) on therapeutic anticoagulation presents with an…
read more here.
Keywords:
thrombolysis;
reversal idarucizumab;
dabigatran reversal;
stroke thrombolysis ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Neurology"
DOI: 10.1212/wnl.0000000000009155
Abstract: Objective To assess the frequency and utilization trends of dabigatran reversal with idarucizumab and compare associated complications, outcomes, and door-to-needle times to those of patients not exposed to idarucizumab in a nationwide cohort of thrombolyzed…
read more here.
Keywords:
dabigatran reversal;
reversal idarucizumab;
idarucizumab;
thrombolyzed patients ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Neurology"
DOI: 10.1212/wnl.0000000000009542
Abstract: In the article “Stroke Reperfusion Therapy Following Dabigatran Reversal With Idarucizumab in a National Cohort” by Barber et al.,1 the first sentence in the Methods section should denote this study as providing Class III evidence.…
read more here.
Keywords:
therapy following;
dabigatran reversal;
reperfusion therapy;
reversal idarucizumab ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "Acta medica portuguesa"
DOI: 10.20344/amp.17662
Abstract: Dabigatran is a direct oral anticoagulant used to prevent stroke and systemic embolism in patients with atrial fibrillation. In situations that require the urgent reversal of its anticoagulant activity, such as in the case of…
read more here.
Keywords:
reversal practical;
dabigatran;
dabigatran reversal;
practical approach ... See more keywords